Company profilePharmaceutical#725 of 1,318 in Pakistan✓ No DRAP alerts

FESTEL LAB

Pharmaceutical company · 13 brands · 16 molecules

Ranked #207 of 213 companies in Other Beta-Lactam, Cephalosporins & Penems

13 registered products 12 pharmaceutical brands 16 distinct molecules 0 DRAP alerts

Company overview

13
registered products
12
pharmaceutical brands
16
distinct molecules
2
therapeutic classes
0
DRAP alerts

FESTEL LAB is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 13 product registrations across 16 distinct molecules. Its portfolio is concentrated in Other Beta-Lactam, Cephalosporins & Penems and Blood Glucose Lowering Drugs, Excluding Insulin. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Therapeutic classes

Other Beta-Lactam, Cephalosporins & Penems · 1Blood Glucose Lowering Drugs, Excluding Insulin · 1

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for FESTEL

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.